Comparison Overview

Novo Nordisk

VS

Hetero Drugs Ltd

Novo Nordisk

Novo Alle, Bagsværd, undefined, 2880, DK
Last Update: 2025-12-10
Between 800 and 849

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 64,615
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Hetero Drugs Ltd

India Hyderabad, 500018, IN
Last Update: 2025-12-09
Between 750 and 799

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Novo Nordisk
100%
Compliance Rate
0/4 Standards Verified
Hetero Drugs Ltd
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Novo Nordisk in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hetero Drugs Ltd in 2025.

Incident History — Novo Nordisk (X = Date, Y = Severity)

Novo Nordisk cyber incidents detection timeline including parent company and subsidiaries

Incident History — Hetero Drugs Ltd (X = Date, Y = Severity)

Hetero Drugs Ltd cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
Incidents

No Incident

https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
Incidents

No Incident

FAQ

Novo Nordisk company demonstrates a stronger AI Cybersecurity Score compared to Hetero Drugs Ltd company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Hetero Drugs Ltd company has disclosed a higher number of cyber incidents compared to Novo Nordisk company.

In the current year, Hetero Drugs Ltd company and Novo Nordisk company have not reported any cyber incidents.

Neither Hetero Drugs Ltd company nor Novo Nordisk company has reported experiencing a ransomware attack publicly.

Neither Hetero Drugs Ltd company nor Novo Nordisk company has reported experiencing a data breach publicly.

Neither Hetero Drugs Ltd company nor Novo Nordisk company has reported experiencing targeted cyberattacks publicly.

Neither Novo Nordisk company nor Hetero Drugs Ltd company has reported experiencing or disclosing vulnerabilities publicly.

Neither Novo Nordisk nor Hetero Drugs Ltd holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Novo Nordisk company nor Hetero Drugs Ltd company has publicly disclosed detailed information about the number of their subsidiaries.

Novo Nordisk company employs more people globally than Hetero Drugs Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Novo Nordisk nor Hetero Drugs Ltd holds SOC 2 Type 1 certification.

Neither Novo Nordisk nor Hetero Drugs Ltd holds SOC 2 Type 2 certification.

Neither Novo Nordisk nor Hetero Drugs Ltd holds ISO 27001 certification.

Neither Novo Nordisk nor Hetero Drugs Ltd holds PCI DSS certification.

Neither Novo Nordisk nor Hetero Drugs Ltd holds HIPAA certification.

Neither Novo Nordisk nor Hetero Drugs Ltd holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N